2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Inhibition of MicroRNA 6937 Delays Photoreceptor and Vision Loss in a Mouse Model of Retinitis Pigmentosa

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Inherited retinal dystrophies (IRDs) are a group of rare retinal conditions, including retinitis pigmentosa (RP), caused by monogenic mutations in 1 out of more than 250 genes. Despite recent advancements in gene therapy, there is still a lack of an effective treatment for this group of retinal conditions. MicroRNAs (miRNAs) are a class of highly conserved small non-coding RNAs that inhibit gene expression. Control of miRNAs-mediated protein expression has been described as a widely used mechanism for post-transcriptional regulation in many physiological and pathological processes in different organs, including the retina. Our main purpose was to test the hypothesis that modulation of a group of miRNAs can protect photoreceptor cells from death in the rd10 mouse model of retinitis pigmentosa. For this, we incorporated modulators of three miRNAs in adeno-associated viruses (AAVs), which were administered through sub-retinal injections. The results obtained indicate that inhibition of the miR-6937-5p slows down the visual deterioration of rd10 mice, reflected by an increased electroretinogram (ERG) wave response under scotopic conditions and significant preservation of the outer nuclear layer thickness. This work contributes to broadening our knowledge on the molecular mechanisms underlying retinitis pigmentosa and supports the development of novel therapeutic approaches for RP based on miRNA modulation.

          Related collections

          Most cited references53

          • Record: found
          • Abstract: found
          • Article: not found

          MicroRNA therapeutics: towards a new era for the management of cancer and other diseases

          MicroRNAs (miRNAs) are small non-coding RNAs that can modulate mRNA expression. Insights into the roles of miRNAs in development and disease have led to the development of new therapeutic approaches that are based on miRNA mimics or agents that inhibit their functions (antimiRs), and the first such approaches have entered the clinic. This Review discusses the role of different miRNAs in cancer and other diseases, and provides an overview of current miRNA therapeutics in the clinic.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            MicroRNA

            MicroRNAs (miRNAs) are small endogenous RNAs that regulate gene-expression posttranscriptionally. MiRNA research in allergy is expanding because miRNAs are crucial regulators of gene expression and promising candidates for biomarker development. MiRNA mimics and miRNA inhibitors currently in preclinical development have shown promise as novel therapeutic agents. Multiple technological platforms have been developed for miRNA isolation, miRNA quantitation, miRNA profiling, miRNA target detection, and modulating miRNA levels in vitro and in vivo. Here we will review the major technological platforms with consideration given for the advantages and disadvantages of each platform.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Toward microRNA-based therapeutics for heart disease: the sense in antisense.

              MicroRNAs act as negative regulators of gene expression by inhibiting the translation or promoting the degradation of target mRNAs. Because individual microRNAs often regulate the expression of multiple target genes with related functions, modulating the expression of a single microRNA can, in principle, influence an entire gene network and thereby modify complex disease phenotypes. Recent studies have identified signature expression patterns of microRNAs associated with pathological cardiac hypertrophy, heart failure, and myocardial infarction in humans and mouse models of heart disease. Gain- and loss-of-function studies in mice have revealed profound and unexpected functions for these microRNAs in numerous facets of cardiac biology, including the control of myocyte growth, contractility, fibrosis, and angiogenesis, providing glimpses of new regulatory mechanisms and potential therapeutic targets for heart disease. Especially intriguing is the discovery of a network of muscle-specific microRNAs embedded within myosin heavy chain genes, which control myosin expression and the response of the heart to stress and thyroid hormone signaling. Disease-inducing cardiac microRNAs can be persistently silenced in vivo through systemic delivery of antimiRs, allowing for the direct therapeutic modulation of disease mechanisms. Here, we summarize current knowledge of the roles of miRNAs in heart disease and consider the advantages and potential challenges of microRNA-based approaches compared to conventional drug-based therapies.
                Bookmark

                Author and article information

                Journal
                Pharmaceutics
                Pharmaceutics
                pharmaceutics
                Pharmaceutics
                MDPI
                1999-4923
                24 September 2020
                October 2020
                : 12
                : 10
                : 913
                Affiliations
                [1 ]Sensorial Neurodegeneration Group, Biodonostia Health Research Institute, 20014 San Sebastian, Spain; anasagasti.85@ 123456gmail.com (A.A.); araceli.lara@ 123456biodonostia.org (A.L.-L.); leire.escudero@ 123456biodonostia.org (L.E.-A.); maria.rodriguezhidalgo@ 123456biodonostia.org (M.R.-H.)
                [2 ]Viralgen Vector Core, 20009 San Sebastián, Spain
                [3 ]Visual Neurophysiology, IRYCIS, University of Alcala, 28801 Madrid, Spain; santiago.milla@ 123456edu.uah.es (S.M.-N.); pedro.villa@ 123456uah.es (P.d.l.V.)
                [4 ]Gene Therapy and Regulation of Gene Expression Program, CIMA, FIMA, University of Navarra, Navarra Institute for Health Research (IdisNA), 31008 Pamplona, Spain; nzabaleta@ 123456unav.es (N.Z.); ggasegui@ 123456unav.es (G.G.A.)
                [5 ]RETICS OFTARED, 28040 Madrid, Spain
                Author notes
                [* ]Correspondence: javiruizederra@ 123456yahoo.es ; Tel.: +34-943-006128
                Author information
                https://orcid.org/0000-0002-4348-3271
                https://orcid.org/0000-0002-1600-4562
                https://orcid.org/0000-0001-8486-8592
                Article
                pharmaceutics-12-00913
                10.3390/pharmaceutics12100913
                7598722
                32987664
                c62e2e92-ed8c-4d82-acf2-9f6133a34ee0
                © 2020 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                : 01 September 2020
                : 17 September 2020
                Categories
                Article

                microrna,mirna,mir,retina,retinal disease,ird,rp,photoreceptor,mirna-mrna interaction,rd10,mouse models,whole transcriptome

                Comments

                Comment on this article